Driving breakthroughs since 1983
GHESKIO has been conducting groundbreaking research with international impact since 1983, when we published the first description of HIV/AIDS in a developing country in the New England Journal of Medicine. Our HIV/AIDS research has resulted in more successful global guidelines, particularly in the early stages of the disease.
Over the last 40 years, our investigators have conducted research that’s been published in more than 200 peer-reviewed papers. Our research has led to treatment outcomes rivaling those of medical centers in the U.S. at a fraction of the cost. Our dedication and quality have been recognized with uninterrupted support since 1983 from the National Institutes of Health.
Current partners include:
Here are some of our key research areas.
TB research unit
Tuberculosis (TB) – especially drug-resistant strains – continues to plague the developing world, including Haiti. Along with international research partners, our investigators strive to understand this complex disease so we can reduce life-threatening TB infections around the world.
NIAID HIV clinical trials
GHESKIO continues its legacy of HIV research through the AIDS Clinical Trials Group (ACTG) and International Maternal, Pediatric and Adolescent AIDS Trials Group (IMPAACT). This program includes eight NIAID therapeutic trials.
Not only do clinical trials generate important research findings, they also help us develop the next generation of researchers. The rigor and knowledge gained from participating in clinical trials prepares trainee researchers to assume leadership roles in future clinical trials.
Cardiovascular disease
Cardiovascular disease (CVD) is now the leading cause of death in Haitian adults.
We recently began studies to help prevent CVD and improve health outcomes of Haitians in both Haiti and in the U.S.
